TACE Associated to Systemic Bevacizumab for the Treatment of Refractory Liver Metastases From Colorectal Cancer
Conditions
- Liver Metastasis Colon Cancer
Interventions
- DEVICE: TACE+ systemic Bevacizumab
- DRUG: FOLFIRI+Bevacizumab
- DEVICE: TACE
Sponsor
Giammaria Fiorentini